Comparing baseline variables and outcomes for CP-CML patients receiving asciminib at 200 mg twice daily (phase 1 study) or dose-modified ponatinib (OPTIC)
| . | Asciminib 200 mg twice daily18 . | Ponatinib 45 mg (OPTIC)13 . | Ponatinib 30 mg (OPTIC)13 . | Comments . |
|---|---|---|---|---|
| No. of patients | 52 | 94 | 94 | |
| Follow-up | 17 mo | 32 mo | 32 mo | |
| Molecular status at baseline | BCR::ABL1IS 54%> 10% 25% 1-10% 15% <1% | |||
| Prior ponatinib therapy | 28/52 (54%) | NA | NA | |
| Results | ||||
| Discontinued therapy | 17/52 (33%) | 44/94 (47%) For all patients on 45 mg, not just T315I cohort | 53/95 (56%) For all patients on 30 mg, not just T315I cohort | Asciminib appears to be better tolerated |
| MMR rate at 12 mo | 12/21 (57%) in ponatinib-naive cohort | NA | NA | |
| MMR rate at 24 mo | 14/21 (66%) in ponatinib-naive cohort | NA | NA | |
| MR2 at 12 mo | NA | 15/25 (60%) | 5/20 (25%) | |
| MR2 at 24 mo | NA | |||
| AOEs | 2/52 (4%) | 9/94 (9.6%) | 5/94 (5.3%) | AOE risk with asciminib may be similar to ponatinib 30 mg (OPTIC dosing) |
| . | Asciminib 200 mg twice daily18 . | Ponatinib 45 mg (OPTIC)13 . | Ponatinib 30 mg (OPTIC)13 . | Comments . |
|---|---|---|---|---|
| No. of patients | 52 | 94 | 94 | |
| Follow-up | 17 mo | 32 mo | 32 mo | |
| Molecular status at baseline | BCR::ABL1IS 54%> 10% 25% 1-10% 15% <1% | |||
| Prior ponatinib therapy | 28/52 (54%) | NA | NA | |
| Results | ||||
| Discontinued therapy | 17/52 (33%) | 44/94 (47%) For all patients on 45 mg, not just T315I cohort | 53/95 (56%) For all patients on 30 mg, not just T315I cohort | Asciminib appears to be better tolerated |
| MMR rate at 12 mo | 12/21 (57%) in ponatinib-naive cohort | NA | NA | |
| MMR rate at 24 mo | 14/21 (66%) in ponatinib-naive cohort | NA | NA | |
| MR2 at 12 mo | NA | 15/25 (60%) | 5/20 (25%) | |
| MR2 at 24 mo | NA | |||
| AOEs | 2/52 (4%) | 9/94 (9.6%) | 5/94 (5.3%) | AOE risk with asciminib may be similar to ponatinib 30 mg (OPTIC dosing) |
Data reproduced with permission from Cortes et al,13 Hughes et al14 , and Cortes et al.18
CCyR, complete cytogenetic response; CHR, complete hematologic response; NA, not available.